Sagimet Biosciences Inc. Increase Decrease In Operating Lease Liability
Sagimet Biosciences Inc. (SGMT) reported Increase Decrease In Operating Lease Liability of -$78.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Sagimet Biosciences Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$39.00K.
- Sagimet Biosciences Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$39.00K.
- Sagimet Biosciences Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$37.00K.
- Sagimet Biosciences Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$37.00K.
- Sagimet Biosciences Inc. increase decrease in operating lease liability for fiscal 2025 was -$152.00K.
- Sagimet Biosciences Inc. increase decrease in operating lease liability for fiscal 2024 was -$136.00K.
- Sagimet Biosciences Inc. increase decrease in operating lease liability for fiscal 2023 was -$146.00K.
- Sagimet Biosciences Inc. increase decrease in operating lease liability for fiscal 2022 was -$137.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$78.00K 10-Q · filed 2026-08-11 | -$115.00K derived: sum of 3 quarters · filed 2026-08-11 | -$152.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$39.00K 10-Q · filed 2026-05-12 | -$76.00K derived: sum of 2 quarters · filed 2026-05-12 | -$113.00K derived: sum of 3 quarters · filed 2026-05-12 | -$152.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$74.00K derived: sum of 2 quarters · filed 2026-03-11 | -$113.00K derived: sum of 3 quarters · filed 2026-08-11 | -$152.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | -$37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$76.00K derived: sum of 2 quarters · filed 2026-08-11 | -$115.00K 10-Q · filed 2025-11-13 | -$153.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$78.00K 10-Q · filed 2026-08-11 | -$116.00K derived: sum of 3 quarters · filed 2026-08-11 | -$153.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$39.00K 10-Q · filed 2026-05-12 | -$77.00K derived: sum of 2 quarters · filed 2026-05-12 | -$114.00K derived: sum of 3 quarters · filed 2026-05-12 | -$136.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$75.00K derived: sum of 2 quarters · filed 2026-03-11 | -$97.00K derived: sum of 3 quarters · filed 2026-03-11 | -$136.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | -$37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$59.00K derived: sum of 2 quarters · filed 2025-11-13 | -$98.00K 10-Q · filed 2025-11-13 | -$136.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$61.00K 10-Q · filed 2025-08-13 | -$99.00K derived: sum of 3 quarters · filed 2025-08-13 | -$136.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$39.00K 10-Q · filed 2025-05-08 | -$77.00K derived: sum of 2 quarters · filed 2025-05-08 | -$114.00K derived: sum of 3 quarters · filed 2025-05-08 | -$150.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$75.00K derived: sum of 2 quarters · filed 2025-03-12 | -$111.00K derived: sum of 3 quarters · filed 2025-03-12 | -$146.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | -$37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$73.00K derived: sum of 2 quarters · filed 2024-11-14 | -$108.00K 10-Q · filed 2024-11-14 | -$142.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$71.00K 10-Q · filed 2024-08-14 | -$105.00K derived: sum of 3 quarters · filed 2024-08-14 | -$139.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$35.00K 10-Q · filed 2024-05-15 | -$69.00K derived: sum of 2 quarters · filed 2024-05-15 | -$103.00K derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$68.00K derived: sum of 2 quarters · filed 2024-03-25 | -$137.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$103.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$69.00K 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |